526 related articles for article (PubMed ID: 11581056)
41. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Dajcs JJ; Thibodeaux BA; Marquart ME; Girgis DO; Traidej M; O'Callaghan RJ
Antimicrob Agents Chemother; 2004 Jun; 48(6):1948-52. PubMed ID: 15155183
[TBL] [Abstract][Full Text] [Related]
42. Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin.
Fuchs PC; Barry AL; Brown SD
J Chemother; 1997 Dec; 9(6):391-3. PubMed ID: 9491837
[TBL] [Abstract][Full Text] [Related]
43. The susceptibility of Streptococcus pneumoniae to levofloxacin and other antibiotics.
Keller N; Smollen G; Davidson Y; Barzilai A; Keren G; Rubinstein E
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():1-3. PubMed ID: 10404329
[TBL] [Abstract][Full Text] [Related]
44. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Bosso JA; Mauldin PD
Antimicrob Agents Chemother; 2006 Jun; 50(6):2106-12. PubMed ID: 16723572
[TBL] [Abstract][Full Text] [Related]
45. [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
Wang ZQ; Li L; Li R; Luo SY; Bai XQ; Liang QF; Deng SJ; Sun XG
Zhonghua Yan Ke Za Zhi; 2008 Mar; 44(3):233-6. PubMed ID: 18785547
[TBL] [Abstract][Full Text] [Related]
46. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens.
Callegan MC; Booth MC; Gilmore MS
Cornea; 2000 Jul; 19(4):539-45. PubMed ID: 10928774
[TBL] [Abstract][Full Text] [Related]
47. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
48. The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible Haemophilus influenzae in comparison with ofloxacin, ciprofloxacin and sparfloxacin.
Dabernat H
Int J Antimicrob Agents; 1999 Feb; 11(2):139-43. PubMed ID: 10221417
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.
Fuchs PC; Barry AL; Brown SD
Antimicrob Agents Chemother; 1996 Jul; 40(7):1633-9. PubMed ID: 8807053
[TBL] [Abstract][Full Text] [Related]
50. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
[TBL] [Abstract][Full Text] [Related]
51. In vitro activity of levofloxacin against gram-positive bacteria.
Montanari MP; Mingoia M; Marchetti F; Varaldo PE
Chemotherapy; 1999; 45(6):411-7. PubMed ID: 10567771
[TBL] [Abstract][Full Text] [Related]
52. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
Casellas JM; Gilardoni M; Tome G; Goldberg M; Ivanovic S; Orduna M; Dolmann A; Ascoli M; Ariza H; Montero JM
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():37-42. PubMed ID: 10404336
[TBL] [Abstract][Full Text] [Related]
53. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals.
Bhavnani SM; Callen WA; Forrest A; Gilliland KK; Collins DA; Paladino JA; Schentag JJ
Am J Health Syst Pharm; 2003 Oct; 60(19):1962-70. PubMed ID: 14531241
[TBL] [Abstract][Full Text] [Related]
54. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
Madaras-Kelly KJ; Demasters TA
Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
[TBL] [Abstract][Full Text] [Related]
55. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
MacGowan AP; Wootton M; Holt HA
J Antimicrob Chemother; 1999 Mar; 43(3):345-9. PubMed ID: 10223589
[TBL] [Abstract][Full Text] [Related]
56. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis.
Li SA; Liu J; Xiang Y; Wang YJ; Lee WH; Zhang Y
Antimicrob Agents Chemother; 2014 Jun; 58(6):3144-50. PubMed ID: 24637683
[TBL] [Abstract][Full Text] [Related]
58. Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.
Song A; McCulley TJ; Lam BL; Feuer WJ; Miller D; Alfonso EC
Am J Ophthalmol; 2001 Jun; 131(6):795-6. PubMed ID: 11384579
[TBL] [Abstract][Full Text] [Related]
59. Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Thibodeaux BA; Dajcs JJ; Caballero AR; Marquart ME; Girgis DO; O'Callaghan RJ
Curr Eye Res; 2004 May; 28(5):337-42. PubMed ID: 15287370
[TBL] [Abstract][Full Text] [Related]
60. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
